Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS - Takeaways - MDSpire

Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS

  • By

  • Yue Xi

  • Ying Liang

  • Zhi Chen

  • Lei Lei

  • Lan Mi

  • Xiaoyu Tian

  • Liuyu Sun

  • Qiang Sun

  • Nan Zhou

  • April 23, 2026

  • 0 min

Share

  • 1

    Rituximab effectively reduces relapses in children with steroid-dependent or frequently relapsing nephrotic syndrome due to MCD or FSGS.

  • 2

    In a study of 42 pediatric patients, 90.5% achieved complete remission after rituximab treatment, with a significant decrease in relapse frequency.

  • 3

    The median age of patients at diagnosis was 5.1 years, with a male predominance of 67% during the 6-year follow-up.

  • 4

    No significant difference in relapse rates was found between patients receiving different doses of rituximab during the initial treatment.

  • 5

    While rituximab was well tolerated, findings regarding FSGS require caution due to the small sample size and need for larger studies.

Original Source(s)

Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS

  • by Yue Xi, Ying Liang, Zhi Chen, Lei Lei, Lan Mi, Xiaoyu Tian, Liuyu Sun, Qiang Sun, Nan Zhou

  • April 23, 2026

Related Content

Approaches to Addressing Hypogammaglobulinemia in Pediatric Patients with Refractory Lupus Nephritis: Emphasizing the Role of Belimumab

Case Report: Case studies evaluating anti-HER2 therapy as a tumor-agnostic strategy in rare malignancies

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications